BluePath Capital Management LLC Has $538,000 Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

BluePath Capital Management LLC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,340 shares of the biopharmaceutical company’s stock after purchasing an additional 220 shares during the quarter. BluePath Capital Management LLC’s holdings in Gilead Sciences were worth $538,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Capital World Investors lifted its position in shares of Gilead Sciences by 2.0% in the fourth quarter. Capital World Investors now owns 83,364,123 shares of the biopharmaceutical company’s stock valued at $6,753,350,000 after buying an additional 1,642,736 shares during the last quarter. Capital Research Global Investors increased its stake in shares of Gilead Sciences by 3.0% in the 4th quarter. Capital Research Global Investors now owns 59,657,126 shares of the biopharmaceutical company’s stock valued at $4,832,824,000 after purchasing an additional 1,743,418 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Gilead Sciences by 14.4% in the 4th quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock valued at $1,509,227,000 after purchasing an additional 2,350,550 shares during the last quarter. Morgan Stanley increased its stake in shares of Gilead Sciences by 0.9% in the 3rd quarter. Morgan Stanley now owns 16,909,619 shares of the biopharmaceutical company’s stock valued at $1,267,207,000 after purchasing an additional 158,794 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Gilead Sciences in the 4th quarter valued at $1,301,624,000. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on GILD shares. Barclays reduced their price objective on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a research report on Monday, April 29th. UBS Group cut their target price on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Oppenheimer reaffirmed an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a report on Friday, April 19th. Morgan Stanley cut their target price on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. Twelve research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Hold” and an average price target of $83.47.

Gilead Sciences Price Performance

Shares of GILD traded down $1.81 during trading hours on Wednesday, reaching $66.59. 3,977,325 shares of the stock traded hands, compared to its average volume of 7,584,282. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86. The company’s 50-day moving average price is $66.04 and its two-hundred day moving average price is $72.33. The company has a market cap of $82.96 billion, a P/E ratio of 186.14, a price-to-earnings-growth ratio of 2.92 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. The firm had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.37 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 3.75 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.63%. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the transaction, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.29% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.